| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Human Neurochemical Pathology Laboratory (Dr. Guttman), Clarke Institute of Psychiatry and Division of Neurology, University of Toronto, Canada.
Address correspondence and reprint requests to Dr. Mark Guttman, 377 Church Street #407, Markham, Ontario, Canada L6B 1A1.
Pramipexole is a new, selective, nonergoline dopamine agonist that acts on D2 and preferentially on D3 dopamine receptors. Phase II and III clinical trials have shown this drug to be useful in treating both early and advanced Parkinson's disease (PD) patients. A double-blind, randomized, multicenter study was performed to compare the safety, tolerance, and efficacy of pramipexole versus placebo in patients with advanced PD with motor fluctuations. A bromocriptine treatment group was included to enable comparisons between bromocriptine and placebo groups, but the study was not powered to show statistical differences between the active treatment groups. The study included 247 patients with "wearing off." Patients were Hoehn and Yahr stages II to IV during "on" times. The trial included three phases: dose escalation, 6 months' maintenance, and dose reduction. The primary end points were the Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III. Up to 4.5 mg per day of pramipexole and 30 mg per day of bromocriptine were used. The results of the study showed that the UPDRS part II improved by 26.7% for pramipexole (p = 0.0002) and 14% for bromocriptine(p = 0.02) versus 4.8% for placebo. The UPDRS part III showed improvements of 34% for pramipexole (p = 0.0006) and 23.8% for bromocriptine (p = 0.01) versus 5.7% for placebo. There were no major differences in safety data. In the active treatment groups there were more reports of dyskinesia and nausea compared with placebo. In regard to comparison of the Global Clinical Assessment of Efficacy between active treatment groups, there was a trend to significance (p = 0.056) in favor of pramipexole. We conclude that pramipexole-treated patients with advanced PD improved significantly more than placebo for both primary end points.
Supported by Boehringer Ingelheim, Ingelheim am Rhein, Germany. Dr. Guttman is supported by a Center of Excellence Award from the National Parkinson Foundation, Inc., Miami, FL.
Received February 12, 1997. Accepted in final form April 21, 1997.
*Members of the International Pramipexole-Bromocriptine Study Group are listed in the Appendix on page 1065.
This article has been cited by other articles:
|
|
 |
|
  W. Poewe Treatments for Parkinson disease--past achievements and current clinical needs Neurology, February 17, 2009; 72(7_Supplement_2): S65 - S73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Waters and J. J. Chen Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off'' Journal of Pharmacy Practice, August 1, 2008; 21(4): 254 - 261. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Kleiner-Fisman and D. N. Fisman Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole Arch Neurol, June 1, 2007; 64(6): 820 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. LeWitt, K. E. Lyons, R. Pahwa, and on behalf of the SP 650 Study Group Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study Neurology, April 17, 2007; 68(16): 1262 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pahwa, M. A. Stacy, S. A. Factor, K. E. Lyons, F. Stocchi, B. P. Hersh, L. W. Elmer, D. D. Truong, N. L. Earl, and on behalf of the EASE-PD Adjunct Study Investigato Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease Neurology, April 3, 2007; 68(14): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pahwa, S. A. Factor, K. E. Lyons, W. G. Ondo, G. Gronseth, H. Bronte-Stewart, M. Hallett, J. Miyasaki, J. Stevens, and W. J. Weiner Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, April 11, 2006; 66(7): 983 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Marinus, M Visser, A M Stiggelbout, J M. Rabey, P Martinez-Martin, U Bonuccelli, P H Kraus, and J J van Hilten A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA J. Neurol. Neurosurg. Psychiatry, March 1, 2004; 75(3): 388 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Shults Treatments of Parkinson Disease: Circa 2003 Arch Neurol, December 1, 2003; 60(12): 1680 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guttman, S. J. Kish, and Y. Furukawa Current concepts in the diagnosis and management of Parkinson's disease Can. Med. Assoc. J., February 4, 2003; 168(3): 293 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Pogarell, T Gasser, J J van Hilten, S Spieker, S Pollentier, D Meier, and W H Oertel Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study J. Neurol. Neurosurg. Psychiatry, June 1, 2002; 72(6): 713 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Adler Relevance of motor complications in Parkinson's disease Neurology, February 1, 2002; 58(90001): S51 - 56. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Elble Tremor and dopamine agonists Neurology, February 1, 2002; 58(90001): S57 - 62. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Lees, R. Katzenschlager, J. Head, and Y. Ben-Shlomo Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial Neurology, November 13, 2001; 57(9): 1687 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]
|
|
|
|
 |
|
 A Münchau and K P Bhatia Pharmacological treatment of Parkinson's disease Postgrad. Med. J., October 1, 2000; 76(900): 602 - 610. [Full Text]
|
|
|
|
|
|
D J BROOKS Dopamine agonists: their role in the treatment of Parkinson's disease J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 685 - 689. [Full Text] [PDF]
|
|
|
|
|
|
E.-K. Tan and W. Ondo Clinical Characteristics of Pramipexole-Induced Peripheral Edema Arch Neurol, May 1, 2000; 57(5): 729 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic New and Emerging Therapies for Parkinson Disease Arch Neurol, July 1, 1999; 56(7): 785 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Developments in the treatment of Parkinson's disease DTB, May 1, 1999; 37(5): 36 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M M Pinter, O Pogarell, and W H Oertel Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study J. Neurol. Neurosurg. Psychiatry, April 1, 1999; 66(4): 436 - 441. [Abstract] [Full Text]
|
|
|
|
|
|
C. G. Goetz, L. Blasucci, and G. T. Stebbins Switching dopamine agonists in advanced Parkinson's disease: Is rapid titration preferable to slow? Neurology, April 1, 1999; 52(6): 1227 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pahwa, S. A. Factor, K. E. Lyons, W. G. Ondo, G. Gronseth, H. Bronte-Stewart, M. Hallett, J. Miyasaki, J. Stevens, and W. J. Weiner Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, April 11, 2006; 66(7): 983 - 995. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
